Analysts downgraded AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Central European Distribution Corp (NASDAQ: CEDC), Chesapeake Energy (NYSE: CHK), Concur Technologies, Inc. (NASDAQ: CNQR) and DigitalGlobe Inc (NYSE: DGI) today.
JPMorgan Chase & Co. (NYSE:JPM) downgraded AMAG Pharmaceuticals, Inc. (AMAG) from an “overweight” rating to a “neutral” rating.
Goldman Sachs (NYSE:GS) downgraded Central European Distribution Corp (CEDC) from a “buy” rating to a “neutral” rating.
Global Hunter Securities downgraded Chesapeake Energy (CHK) from a “buy” rating to an “accumulate” rating. They have a price target of $39.00 on the company.
Gleacher & Co. downgraded Concur Technologies, Inc. (CNQR) from a “buy” rating to a “neutral” rating.
The Benchmark Company downgraded DigitalGlobe Inc (DGI) from a “buy” rating to a “hold” rating. They have a price target of $30.00 on the company, down previously from $38.00.
Showing posts with label AMAG. Show all posts
Showing posts with label AMAG. Show all posts
Wednesday, May 4, 2011
Ratings On (AMAG) (AMX) (ANAD) (BGFV) (CCC) Downgraded by Analysts
Analysts downgraded AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), America Movil S.A.B. de C.V. (NYSE: AMX), ANADIGICS, Inc. (NASDAQ: ANAD), Big 5 Sporting Goods (NASDAQ: BGFV) and Calgon Carbon Corp (NYSE: CCC) today.
Leerink downgraded AMAG Pharmaceuticals, Inc. (AMAG) from an “outperform” rating to a “market perform” rating.
Wells Fargo & Co. (NYSE:WFC) downgraded America Movil S.A.B. de C.V. (AMX) from an “outperform” rating to a “market perform” rating.
Raymond James (NYSE:RJF) downgraded ANADIGICS, Inc. (ANAD) from a “market perform” rating to an “underperform” rating.
Feltl & Co. downgraded Big 5 Sporting Goods (BGFV) from a “buy” rating to a “hold” rating. They have a price target of $12.00 on the company, down from $15.00.
Oppenheimer downgraded Calgon Carbon Corp (CCC) from an “outperform” rating to a “perform” rating.
Leerink downgraded AMAG Pharmaceuticals, Inc. (AMAG) from an “outperform” rating to a “market perform” rating.
Wells Fargo & Co. (NYSE:WFC) downgraded America Movil S.A.B. de C.V. (AMX) from an “outperform” rating to a “market perform” rating.
Raymond James (NYSE:RJF) downgraded ANADIGICS, Inc. (ANAD) from a “market perform” rating to an “underperform” rating.
Feltl & Co. downgraded Big 5 Sporting Goods (BGFV) from a “buy” rating to a “hold” rating. They have a price target of $12.00 on the company, down from $15.00.
Oppenheimer downgraded Calgon Carbon Corp (CCC) from an “outperform” rating to a “perform” rating.
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Tuesday, January 11, 2011
AMAG Pharmaceuticals' (NASDAQ:AMAG) IV iron, Feraheme Sales Down
A preview of the fourth quarter of AMAG Pharmaceuticals' (NASDAQ:AMAG) IV iron and Feraheme suggests sales are down, and Canaccord lowered their estimates on the company in response.
Canaccord said, "We are lowering our estimates, which results in a new price target of $16. AMAG’s Q4/10 preview indicates that sales of its IV iron, Feraheme, are below our expectations. There is a lingering overhang related to safety issues and recent label changes, and the long-term impact on the sales trend is not yet clear. While the valuation might look cheap here, we maintain a cautious stance."
Canaccord Genuity maintains a "Hold" on AMAG Pharmaceuticals, which closed Monday at $16.69, dropping $1.31, or 7.28 percent. Canaccord increased their price target on them from $16 to $19.
Canaccord said, "We are lowering our estimates, which results in a new price target of $16. AMAG’s Q4/10 preview indicates that sales of its IV iron, Feraheme, are below our expectations. There is a lingering overhang related to safety issues and recent label changes, and the long-term impact on the sales trend is not yet clear. While the valuation might look cheap here, we maintain a cautious stance."
Canaccord Genuity maintains a "Hold" on AMAG Pharmaceuticals, which closed Monday at $16.69, dropping $1.31, or 7.28 percent. Canaccord increased their price target on them from $16 to $19.
Monday, November 29, 2010
AMAG Pharma (AMAG) Says No 'Black Box' Warning on Feraheme Label
After a press release from AMAG Pharma (NASDAQ:AMAG) saying they won't be including a "Black Box" warning on their Feraheme drug label, shares in the company have soared by over 14 percent on the day.
Feraheme is the main growth vehicle of the company at this time, and expectations on the Street were they would be hit with a Black Box warning. News they weren't surprised most people and caused them to pour money into the stock.
There are still a lot of questions that Amag will need to answer, but for now it's a probably first step toward turning things slowly around.
AMAG was trading at $16.05, soaring by $2.00, or 14.23 percent at 1:02 PM EST.
Feraheme is the main growth vehicle of the company at this time, and expectations on the Street were they would be hit with a Black Box warning. News they weren't surprised most people and caused them to pour money into the stock.
There are still a lot of questions that Amag will need to answer, but for now it's a probably first step toward turning things slowly around.
AMAG was trading at $16.05, soaring by $2.00, or 14.23 percent at 1:02 PM EST.
Subscribe to:
Posts (Atom)